Modulation of Ciliogenesis in Glioma Stem Cells (RF2019-1236878)

Institute of Hospitalization and Scientific Care (IRCCS)

Status: Completed

Conditions: Glioblastoma; Glioma, Malignant

Treatments: Diagnostic Test: Validating ciliogenesis players; Other: Dissecting ciliogenesis players; Other: Biological sample collection

Study type: Interventional

Funder types: Other

Identifiers

NCT05772767

3782

Details and patient eligibility

About

The study aims at investigating the cilium-related transcriptome in patients-derived glioblastoma stem cells and the potential impact of modulation of cilium players in vitro, in vivo and ex vivo in glioblastoma brain organoids. Moreover, drugs inhibiting cilia disassembly will be tested. Finally, the potential prognostic role of a cilium-related gene expression signature in glioblastoma will be assessed.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

To be enrolled in the study patients must:

1. Have a radiological diagnosis of supratentorial glioblastoma, or
2. Have a radiological diagnosis of first recurrence of a primary supratentorial glioblastoma (for which a formal histopathologic diagnosis of glioblastoma had been made at first surgery), according with RANO criteria (Wen, 2010);
3. Be a candidate to neurosurgery for glioblastoma at the Operational Unit of Neurosurgery FPG;
4. Be of an age of 18 years or above;
5. Provide written informed consent for participation to the study.

Exclusion criteria

To be enrolled in the study patients must not:

1. Have not enough pathological material removed at surgery available both for mandatory routine histopathological diagnosis and for the present study, as judged by the Principal Investigator;
2. Have not a definitive pathological diagnosis of a primary supratentorial GBM, according with 2016 WHO classification.

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Biological sample collection

Other group

Description:

Collection of tumor tissue and PBMC for the generation of glioblastoma stem cell cultures and brain organoids.

Treatment:

Other: Biological sample collection

Other: Dissecting ciliogenesis players

Diagnostic Test: Validating ciliogenesis players